Biomerica Statistics
Total Valuation
Biomerica has a market cap or net worth of $7.96 million. The enterprise value is $7.55 million.
| Market Cap | 7.96M |
| Enterprise Value | 7.55M |
Important Dates
The last earnings date was Thursday, October 15, 2026, after market close.
| Earnings Date | Oct 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biomerica has 4.60 million shares outstanding. The number of shares has increased by 26.67% in one year.
| Current Share Class | 4.60M |
| Shares Outstanding | 4.60M |
| Shares Change (YoY) | +26.67% |
| Shares Change (QoQ) | +6.20% |
| Owned by Insiders (%) | 7.54% |
| Owned by Institutions (%) | 12.73% |
| Float | 4.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.83 |
| Forward PS | n/a |
| PB Ratio | 2.19 |
| P/TBV Ratio | 2.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.74 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.91, with a Debt / Equity ratio of 0.64.
| Current Ratio | 1.91 |
| Quick Ratio | 1.28 |
| Debt / Equity | 0.64 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -113.80% and return on invested capital (ROIC) is -59.00%.
| Return on Equity (ROE) | -113.80% |
| Return on Assets (ROA) | -45.47% |
| Return on Invested Capital (ROIC) | -59.00% |
| Return on Capital Employed (ROCE) | -103.73% |
| Weighted Average Cost of Capital (WACC) | 4.91% |
| Revenue Per Employee | $86,760 |
| Profits Per Employee | -$100,180 |
| Employee Count | 50 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 2.77 |
Taxes
In the past 12 months, Biomerica has paid $26,000 in taxes.
| Income Tax | 26,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.99% in the last 52 weeks. The beta is 0.38, so Biomerica's price volatility has been lower than the market average.
| Beta (5Y) | 0.38 |
| 52-Week Price Change | -37.99% |
| 50-Day Moving Average | 2.06 |
| 200-Day Moving Average | 2.05 |
| Relative Strength Index (RSI) | 37.61 |
| Average Volume (20 Days) | 11,838 |
Short Selling Information
The latest short interest is 10,485, so 0.23% of the outstanding shares have been sold short.
| Short Interest | 10,485 |
| Short Previous Month | 27,659 |
| Short % of Shares Out | 0.23% |
| Short % of Float | 0.25% |
| Short Ratio (days to cover) | 0.45 |
Income Statement
In the last 12 months, Biomerica had revenue of $4.34 million and -$5.01 million in losses. Loss per share was -$1.63.
| Revenue | 4.34M |
| Gross Profit | 41,000 |
| Operating Income | -5.43M |
| Pretax Income | -4.98M |
| Net Income | -5.01M |
| EBITDA | -5.36M |
| EBIT | -5.43M |
| Loss Per Share | -$1.63 |
Balance Sheet
The company has $2.73 million in cash and $2.33 million in debt, with a net cash position of $407,000 or $0.09 per share.
| Cash & Cash Equivalents | 2.73M |
| Total Debt | 2.33M |
| Net Cash | 407,000 |
| Net Cash Per Share | $0.09 |
| Equity (Book Value) | 3.65M |
| Book Value Per Share | 0.79 |
| Working Capital | 2.57M |
Cash Flow
| Operating Cash Flow | -3.96M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 72,000 |
| Net Borrowing | 500,000 |
| Free Cash Flow | -3.96M |
| FCF Per Share | -$0.86 |
Margins
Gross margin is 0.95%, with operating and profit margins of -125.15% and -115.47%.
| Gross Margin | 0.95% |
| Operating Margin | -125.15% |
| Pretax Margin | -114.87% |
| Profit Margin | -115.47% |
| EBITDA Margin | -123.49% |
| EBIT Margin | -125.15% |
| FCF Margin | n/a |
Dividends & Yields
Biomerica does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -26.67% |
| Shareholder Yield | -26.67% |
| Earnings Yield | -94.06% |
| FCF Yield | -49.71% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 21, 2025. It was a reverse split with a ratio of 1:8.
| Last Split Date | Apr 21, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:8 |
Scores
Biomerica has an Altman Z-Score of -10.46 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.46 |
| Piotroski F-Score | 1 |